SAB Biotherapeutics, Inc. (SABS)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

2.98 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$13.27M

Free cash flow

$45.71M

Return on equity

8.8%

Return on capital

-32.3%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
7 Dec 2023	Sullivan Eddie Joe Chief Executive Officer	Bought	$1.53K	0.0%
30 Nov 2023	King Michael CHIEF FINANCIAL OFFICER	Bought	$4.50K	opened
29 Nov 2023	Reich Samuel J Executive Chairman	Bought	$9.84K	5.3%
13 Sep 2022	HAMILTON CHRISTINE E Director	Bought	$7.30K	0.2%
7 Sep 2022	Sullivan Eddie Joe CHIEF EXECUTIVE OFFICER	Bought	$10.32K	0.3%
26 Oct 2021	Beyer Russell P Chief Financial Officer	Sold, plan not stated	$2.20K	100%

34out of 100

Profitability 24

Financial strength 67

Growth 0

Insiders 50

Strongest on financial strength (67), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan